Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial.

  • 2024-08-03
  • Lipids in health and disease 23(1)
    • Yufeng Jin
    • Xin Wang
    • Ke Chen
    • Yu Chen
    • Lixin Zhou
    • Yupeng Zeng
    • Yuqing Zhou
    • Zhijun Pan
    • Di Wang
    • Zhongxia Li
    • Yongqian Liang
    • Wenhua Ling
    • Dan Li

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 83
Population
83 patients with MASLD
Methods
24-week randomized, double-blind, placebo-controlled trial, 83 patients randomized to placebo (n=41) or silymarin (103.2 mg/d, n=42), assessments at 0, 12, and 24 weeks with FibroScan, blood samples, and fecal samples for 16S rRNA sequencing
Blinding
Double-blind
Duration
24 weeks
Funding
Unclear

Background

Despite centuries of traditional use of silymarin for hepatoprotection, current randomized controlled trial (RCT) studies on the effectiveness of silymarin in managing metabolic dysfunction-associated steatotic liver disease (MASLD) are limited and inconclusive, particularly when it is administered alone. The low bioavailability of silymarin highlights the possible influence of gut microbiota on the effectiveness of silymarin; however, no human studies have investigated this aspect.

Objective

To determine the potential efficacy of silymarin in improving MASLD indicators and to investigate the underlying mechanisms related to gut microbiota.

Method

In this 24-week randomized, double-blind, placebo-controlled trial, 83 patients with MASLD were randomized to either placebo (n = 41) or silymarin (103.2 mg/d, n = 42). At 0, 12, and 24 weeks, liver stiffness and hepatic steatosis were assessed using FibroScan, and blood samples were gathered for biochemical detection, while faecal samples were collected at 0 and 24 weeks for 16S rRNA sequencing.

Results

Silymarin supplementation significantly reduced liver stiffness (LSM, -0.21 ± 0.17 vs. 0.41 ± 0.17, P = 0.015) and serum levels of γ-glutamyl transpeptidase (GGT, -8.21 ± 3.01 vs. 1.23 ± 3.16, P = 0.042) and ApoB (-0.02 ± 0.03 vs. 0.07 ± 0.03, P = 0.023) but had no significant effect on the controlled attenuation parameter (CAP), other biochemical indicators (aminotransferases, total bilirubin, glucose and lipid parameters, hsCRP, SOD, and UA), physical measurements (DBP, SBP, BMI, WHR, BF%, and BMR), or APRI and FIB-4 indices. Gut microbiota analysis revealed increased species diversity and enrichment of Oscillospiraceae in the silymarin group.

Conclusion

These findings suggest that silymarin supplementation could improve liver stiffness in MASLD patients, possibly by modulating the gut microbiota.

Trial registration

The trial was registered at the Chinese Clinical Trial Registry (ChiCTR2200059043).

Research Insights

Back to top